Dr. Pri answers the longevity hotline and discusses how to sequence Longevity changes especially when you are busy. He also explains how you can quickly determine if a scientific study's results apply to you. Then he look at some news this week, including a potential breakthrough treatment for the neurodegenerative disorder Huntington's disease.

Where to find us:
Website | https://vitaveda.health
Youtube | https://www.youtube.com/@vitavedahealth
Twitter / X | https://x.com/vitavedahealth
Newsletter | https://substack.com/@vitavedahealth

Timestamps
0:00 Intro
1:16 Longevity Hotline - How to tackle Longevity when you are very busy?
12:57 How to tell if a study’s results apply to you
18:40 Oura ring is now valued at $11 billion, show casing consumer health tech strength
19:40 A 90 year old just got his 9th black belt - another inspiring example of longevity
21:00 A new therapy for Huntington's disease shows promise
 
References:
Hotline - A busy business man had a full check up - where to start?
An informative tweet on Creatine from a helpful account, but what claims can we make from this study?
Oura Ring is now a $11 billion company based on their raise of almost $1bn
This 90 year old martial artist is a reminder that you can get there too!
A new therapy for Huntington's disease shows promise

Disclaimer
This audio and video podcast are for general informational purposes only and does not constitute a practice of medicine, nursing or other professional health care services including the giving of medical advice. No doctor patient relationship is formed. The use of this information and the materials linked to this podcast and video cast are at the user’s own risk. The content on this podcast and video cast are not intended to be a substitute for professional medical advice, diagnosis or treatment. Any listener or watcher of this information should not disregard or delay in obtaining medical advice from any medical condition they have and they should seek assistance of their healthcare professionals for any such conditions. We take all conflicts of interest very seriously. For all disclosures and companies we invest in or advise, please visit our website.